U.S. FDA approves Welireg plus Lenvima for certain previously treated adults with advanced renal cell carcinoma
MRK•The U.S. FDA approved Merck’s Welireg plus Lenvima for certain previously treated adults with advanced renal cell carcinoma with a clear cell component.
1. FDA approval
Merck said the U.S. FDA approved Welireg (belzutifan) plus Lenvima (lenvatinib) for certain previously treated adult patients with advanced renal cell carcinoma with a clear cell component.
